Understanding MDM4: A Potential Drug Target (G4194)

Target Name: MDM4

NCBI ID: G4194

MDM4

Understanding MDM4: A Potential Drug Target

MDM4 (MutL homolog 4) is a gene that encodes a protein known for its role in cell signaling and DNA replication. The protein is a key component of the Mitosis-Induced Maintenance of Genomic Instability (MIMG) complex, which is a network of proteins that helps ensure the proper execution of genetic instructions during cell division.

MDM4 variants have been identified as potential drug targets or biomarkers for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biological and clinical potential of MDM4, with a focus on its potential as a drug target.

The MDM4 protein is a 21-kDa protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It is composed of a unique transmembrane region, a cytoplasmic tail, and a N-terminal intracellular domain. The N-terminal domain is known as the N-terminal alpha-helix, which is a structural element that is involved in the regulation of protein stability and function.

MDM4 is involved in several cellular processes, including cell signaling, DNA replication, and apoptosis (programmed cell death). In addition, it is a key component of the MIMG complex, which is responsible for ensuring the proper execution of genetic instructions during cell division . The MIMG complex includes several other proteins, including p53, which is a well-known tumor suppressor protein, and p21, which is a key regulator of the cell cycle.

MDM4 has been identified as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the main reasons for its potential as a drug target is its involvement in several key cellular processes that are disrupted in these diseases. For example, MDM4 is involved in the regulation of cell signaling, which is often disrupted in cancer cells. In addition, MDM4 is involved in the regulation of DNA replication, which is often disrupted in neurodegenerative diseases. Finally, MDM4 is involved in the regulation of apoptosis, which is often disrupted in autoimmune disorders.

In addition to its involvement in cellular processes, MDM4 is also known for its unique structure and its ability to interact with other proteins. This has led to its potential as a drug target, as drugs that can modulate its function may have a wide range of therapeutic applications. For example, one potential drug that is being developed as a treatment for cancer is an inhibitor of theMDM4 protein. This drug works by inhibiting the activity of the MDM4 protein, which in turn inhibits the formation of the MIMG complex and disrupts the regulation of cellular processes that are often disrupted in cancer.

In conclusion, MDM4 is a protein that is involved in several key cellular processes and has been identified as a potential drug target for several diseases. Its unique structure and ability to interact with other proteins make it an attractive target for drug development. Further research is needed to fully understand the role of MDM4 in cellular processes and its potential as a drug target.

Protein Name: MDM4 Regulator Of P53

Functions: Along with MDM2, contributes to TP53 regulation (PubMed:32300648). Inhibits p53/TP53- and TP73/p73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions

The "MDM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MDM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets